Trimonthly vs. monthly use of bone-targeted agents in patients with bone metastases and multiple myeloma

Record ID 32018001646
Project Status: Ongoing
Anticipated Publish Date: 2022
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Switzerland
MeSH Terms
  • Denosumab
  • Neoplasm Metastasis
  • Bone Density Conservation Agents
  • Bone Neoplasms
  • Zoledronic Acid
  • Multiple Myeloma
  • Ibandronic Acid
  • Diphosphonates
  • bone-targeted agents
  • bone metastases
  • multiple myeloma
  • zoledronate
  • ibandronate
  • denosumab
  • cancer-induced pain
  • hypercalcaemia
  • fracture risk
  • PROMs
  • efficacy
  • effectiveness
  • safety
  • costs
  • economics
  • cost-effectiveness
  • budget impact
  • legal
  • social
  • ethical
  • organisational
Organisation Name: Swiss Federal Office of Public Health (FOPH)
Contact Address: Federal Office of Public Health, Schwarzenburgstrasse 157, CH-3003 Berne, Switzerland
Contact Name: Stephanie Vollenweider
Contact Email:
Copyright: Swiss Federal Office of Public Health
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.